5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a tryptamine found in several plants and in the secretions of the Incilius alvarius toad that is most commonly vaporised and inhaled in naturalistic spiritual and recreational contexts. Dourron and colleagues situate 5-MeO-DMT as an "atypical" psychedelic because, unlike classic psychedelics whose actions are largely attributed to 5-HT2A receptor agonism, the compound shows comparatively low affinity at 5-HT2A (reported Ki ~907 nM) and much higher affinity at 5-HT1A (reported Ki ~3.0 nM). Interest in 5-MeO-DMT has grown because short inhaled sessions (15–30 minutes) could offer a more scalable therapeutic model than longer-acting agents such as psilocybin, and early naturalistic and open-label data suggest potential anxiolytic and antidepressant effects, including in treatment‑resistant depression. This review paper aims to delineate how 5-MeO-DMT's pharmacology, acute and post-acute phenomenology, and adverse-event profile may differ from typical psychedelics, and to propose a novel hypothesis: some of 5-MeO-DMT's distinctive effects and its relatively frequent reports of post-acute "reactivations" might reflect transient epileptiform activity, particularly in medial temporal lobe regions where 5-HT1A receptors are relatively concentrated. The authors argue that clarifying these potential mechanisms is important both for safety monitoring and for optimising therapeutic development, and they call for targeted preclinical and human research to test their proposal.

This article is a narrative review and hypothesis paper synthesising diverse lines of evidence rather than a systematic review with a stated search strategy. The investigators integrate pharmacological binding data, animal behavioural and EEG studies, case reports (including accidental toad secretion ingestion), surveys and naturalistic studies of users, early clinical/open-label trials, and relevant literature on seizures and epilepsy to motivate and evaluate their central hypothesis. Key elements of the approach include: (1) comparing receptor pharmacology across tryptamines and other psychedelics with a focus on 5-HT1A versus 5-HT2A selectivity; (2) reviewing preclinical reports of seizure-like behaviours and EEG changes after 5-MeO-DMT administration across species; (3) assembling phenomenological data from controlled studies, survey research, and harm‑reduction/experience-report sources (e.g., Erowid) to characterise acute effects such as "white-out" experiences and the post-acute phenomenon commonly termed reactivations or flashbacks; and (4) juxtaposing the subjective and behavioural effects of 5-MeO-DMT with clinical descriptions of focal seizures, especially those originating in medial temporal and insular regions. The paper notes where quantitative detail is lacking in the literature and highlights gaps that require empirical testing, but it does not report a formal risk-of-bias assessment or prespecified inclusion criteria.

Pharmacology: The extracted text reports that 5-MeO-DMT displays comparatively low affinity at 5-HT2A receptors and high affinity at 5-HT1A receptors (Ki values cited as ~907 nM and ~3.0 nM respectively). The authors emphasise that 5-MeO-DMT's selectivity for 5-HT1A over 5-HT2A is substantially greater than that of many classic psychedelics, and they cite selectivity ratios reported in the literature (figures appearing in the extraction range from >108-fold to ≈373.6-fold). The review notes the functional complexity of 5-HT1A signalling (pre‑ and post‑synaptic localisation, possible full versus partial agonism, and functional selectivity) and that 5-HT1A agonists can show both pro‑ and anticonvulsant effects depending on context. Preclinical and toxicological evidence: Behavioural reports in animals document seizure or seizure‑like behaviours after 5-MeO-DMT in mice, rats, guinea pigs, sheep and non‑human primates in laboratory settings, although doses and cross-species relevance are not always clear. Case reports include seizures after animals or humans licked Incilius alvarius secretions; these secretions are reported to contain 20–30% 5-MeO-DMT by weight as well as other alkaloids such as bufotenine. Animal EEG data are limited but some studies report trend-level increases in spontaneous paroxysmal activity. Acute phenomenology: 5-MeO-DMT is frequently described as producing a ‘‘white‑out’’ or void-like state with intense affect and often amnesia for the episode, rather than the rich sensory/visual experiences commonly associated with other tryptamines such as DMT. In a small safety dose-finding study (n = 22), 3 participants (13.6%) met criteria for a complete mystical experience after 5-MeO-DMT; this is contrasted with an approximate 60% complete mystical-experience rate reported for high-dose psilocybin in prior studies. Survey and naturalistic data suggest that many users (reported 64% in one survey) describe 5-MeO-DMT as more intense than other psychedelics and that peak‑type experiences are often reported, especially after repeated dosing. Sensitisation and dosing patterns: Evidence of sensitisation is noted in a macaque model after daily dosing over 12 days; clinical reports suggest success with an "individualising dosing regimen" and higher remission rates after successive vaporised doses compared to single higher doses in one small TRD study. The authors raise the possibility of a kindling‑like effect with repeated rapid dosing. Reactivations/flashbacks: Reactivations (the post‑acute re‑experiencing of drug effects) are reported at higher rates after 5-MeO-DMT than after typical psychedelics. Naturalistic prevalence estimates range from 27% to 73%; a TRD clinical study reported reactivations in 25% of participants across dose groups. Reactivations typically occur within days to weeks of use, often have emotional or bodily components rather than primarily visual phenomena, and may be triggered by falling asleep, meditation, or other substances in some cases. Although many reactivations are described as neutral or positive, a minority are negatively valenced—reported as 4% in one sample of ceremonial users (n = 344) and 7% in a general naturalistic sample (N = 169). The authors contrast these patterns with Hallucinogen Persisting Perceptual Disorder (HPPD) as defined in DSM‑V and note that visual HPPD symptoms are reportedly less prominent after 5-MeO-DMT. Comparisons with seizures and other psychedelics: The review documents phenomenological overlap between 5-MeO-DMT effects (white‑outs, amnesia, strong somatic and affective components, automatisms) and focal seizures arising in medially located temporal or insular foci (ecstatic seizures, auras, automatisms, déjà vu). The authors summarise literature implicating 5-HT1A receptor alterations in epilepsy and note that 5-HT1A receptor density is relatively high in medial temporal regions. They also discuss data showing that typical psychedelics can rarely provoke seizures (poison‑control call data give single‑seizure reports for LSD, ayahuasca, psilocybin) but that some classic psychedelics show anticonvulsant properties in preclinical models. NBOMe compounds are highlighted as commonly associated with seizures in adverse reaction reports (seizures reported in 40% of NBOMe adverse reactions), illustrating heterogeneity across serotonergic ligands. Alternative explanations and limitations of the evidence: The authors review alternative accounts for reactivations, including psychological trauma-related reliving, panic‑attack‑like phenomena, and an "alpha‑rebound" oscillatory hypothesis; they note limitations in the existing data (reliance on anecdotal reports, lack of long‑term prospective follow-up, variable definitions of flashbacks/reactivations, and absence of systematic EEG data in humans after 5‑MeO‑DMT).

Dourron and colleagues interpret the assembled evidence as consistent with the characterisation of 5-MeO-DMT as an "atypical" psychedelic that is pharmacologically distinct from typical 5-HT2A‑mediated psychedelics. They argue that 5-MeO-DMT's strong 5-HT1A affinity, its localisation of 5-HT1A receptors in medial temporal regions, the animal seizure data, and the compound's distinctive acute phenomenology and higher reported rate of reactivations collectively motivate the hypothesis that 5-MeO-DMT may evoke transient epileptiform activity in some users. The authors stress that this mechanism, if confirmed, would not necessarily preclude therapeutic use—drawing parallels with electroconvulsive therapy, which intentionally induces seizures and can be an effective antidepressant intervention—and instead would inform safer and more effective development and monitoring strategies. The discussion acknowledges several distinctions between seizures and 5-MeO-DMT experiences (for example, olfactory hallucinations are common in some temporal lobe seizures but not routinely reported with 5-MeO-DMT, and complete mystical experiences are relatively rare in seizures), and notes that expectancy and setting likely modulate subjective reports in naturalistic contexts. The authors also consider that epileptiform activity provoked by 5-MeO-DMT, if present, might differ from canonical temporal lobe seizures and could overlap with phenomena observed in certain meditation practices that can produce seizure‑like EEG patterns. Key limitations are emphasised: the current evidence base is heterogeneous, relies heavily on anecdote and small samples, lacks systematic human EEG and longitudinal follow-up data, and does not yet clarify whether 5-MeO-DMT is a full versus partial agonist at pre‑ versus post‑synaptic 5-HT1A receptors. The authors therefore call for targeted research—ranging from preclinical intracranial EEG and receptor pharmacology studies to systematic phenomenological work and ecological post‑use monitoring—to determine whether epileptiform mechanisms contribute to 5-MeO-DMT's effects and to characterise the prevalence, triggers, time course, and clinical significance of reactivations. They recommend treating reactivations as potential adverse events worthy of systematic surveillance in both research and naturalistic settings.

The authors conclude that 5-MeO-DMT has a distinct pharmacological profile and subjective-effect repertoire compared to typical psychedelics, characterised by high 5-HT1A selectivity, frequent reports of "white‑out" experiences, and an elevated rate of post‑acute reactivations or flashback‑type phenomena. Early clinical and naturalistic data suggest therapeutic potential, but mechanistic research is sparse. Dourron and colleagues urge further basic, clinical, and ecological research to clarify 5-MeO-DMT's mechanisms, to quantify its risks—particularly the possibility of epileptiform activity—and to inform best practices for safe therapeutic development.